A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia (Q21260310)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia |
scientific article |
Statements
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia (English)
0 references
David H Adams
1 reference
Bruce J Kinon
1 reference
Simin Baygani
1 reference
Brian A Millen
1 reference
Isabella Velona
1 reference
Sara Kollack-Walker
1 reference
David P Walling
1 reference
22 May 2013
0 references
13
0 references
1
0 references
143
0 references
1 reference
1 reference